IS5891A - Ný sölt HMG-CoA redúktasatálma - Google Patents

Ný sölt HMG-CoA redúktasatálma

Info

Publication number
IS5891A
IS5891A IS5891A IS5891A IS5891A IS 5891 A IS5891 A IS 5891A IS 5891 A IS5891 A IS 5891A IS 5891 A IS5891 A IS 5891A IS 5891 A IS5891 A IS 5891A
Authority
IS
Iceland
Prior art keywords
hmg
coa reductase
reductase inhibitors
amine salts
preparation
Prior art date
Application number
IS5891A
Other languages
English (en)
Other versions
IS2113B (is
Inventor
Pflaum Zlatko
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of IS5891A publication Critical patent/IS5891A/is
Publication of IS2113B publication Critical patent/IS2113B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS5891A 1998-09-18 2001-03-15 Ný sölt HMG-CoA redúktasatálma IS2113B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800240A SI20070A (sl) 1998-09-18 1998-09-18 Nove soli inhibitorjev HMG-CoA reduktaze
PCT/IB1999/001554 WO2000017150A1 (en) 1998-09-18 1999-09-17 NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS

Publications (2)

Publication Number Publication Date
IS5891A true IS5891A (is) 2001-03-15
IS2113B IS2113B (is) 2006-06-15

Family

ID=20432331

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5891A IS2113B (is) 1998-09-18 2001-03-15 Ný sölt HMG-CoA redúktasatálma

Country Status (15)

Country Link
US (4) US6583295B1 (is)
EP (2) EP1466886A3 (is)
JP (1) JP3834203B2 (is)
KR (1) KR100699368B1 (is)
CN (1) CN1228304C (is)
AT (1) ATE271026T1 (is)
AU (1) AU765373C (is)
CA (1) CA2343646A1 (is)
DE (1) DE69918697T2 (is)
HU (1) HUP0103007A3 (is)
IL (1) IL142055A (is)
IS (1) IS2113B (is)
NZ (1) NZ509583A (is)
SI (1) SI20070A (is)
WO (1) WO2000017150A1 (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0251582A (ja) * 1988-08-12 1990-02-21 Kyokado Eng Co Ltd 地盤注入用薬液
AU782143B2 (en) * 1998-09-18 2005-07-07 Lek Pharmaceuticals D.D. Crystals of the sodium salt of pravastatin
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI1154979T1 (en) * 1999-02-03 2005-10-31 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
CZ20023826A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
WO2002030415A1 (en) * 2000-10-05 2002-04-18 Biogal Gyogyszergyar Rt Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
JP2004536826A (ja) * 2001-06-21 2004-12-09 アンドルックス ファーマスーティカルズ インコーポレーテッド プラバスタチンを含む安定な薬剤組成物
JP2003026634A (ja) * 2001-07-17 2003-01-29 Mercian Corp プラバスタチンナトリウム塩の製造方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
DE60323835D1 (de) * 2002-06-13 2008-11-13 Novartis Ag Calciumsalze von statinen aus indol
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
WO2005014541A1 (en) * 2003-08-12 2005-02-17 Biocon Limited Novel antihypercholesterolemic compound
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US20070276027A1 (en) 2003-09-17 2007-11-29 Warner-Lambert Company Llc Crystalline Forms of [R-(R* ,R*)]-2-(4-Fluorophenyl)-Beta, -Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
CN1894221B (zh) 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
WO2005105738A2 (en) * 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of atorvastatin
WO2006017357A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
CA2576196A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
WO2006072963A1 (en) * 2005-01-10 2006-07-13 Concord Biotech Limited Process for preparing simvastatin from lovastatin amine salts in three steps
WO2006091771A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
BRPI0605917A2 (pt) 2005-08-16 2009-05-26 Teva Pharma intermediário cristalino de rosuvastatina
PL211815B1 (pl) * 2007-11-19 2012-06-29 Inst Chemii Organicznej Polska Akademia Nauk Enzym esteraza lowastatyny osadzony na nośniku nierozpuszczalnym w wodzie, sposób osadzania enzymu, zastosowanie enzymu esterazy lowastatyny osadzonego na nosniku nierozpuszczalnym w wodzie, przepływowy reaktor biokatalityczny ze złożem oraz sposób wytwarzania i/lub oczyszczania symwastatyny
WO2009078033A2 (en) * 2007-12-18 2009-06-25 Themis Medicare Limited Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
WO2011089559A1 (en) * 2010-01-22 2011-07-28 Orchid Chemicals And Pharmaceuticals Limited A novel polymorphic form of atorvastatin salts
WO2012063115A2 (en) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Process for the preparation of rosuvastatin calcium via novel amine intermediate
CN114031496A (zh) * 2021-11-30 2022-02-11 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
ES493726A0 (es) 1979-07-27 1981-06-16 Sankyo Co Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos.
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS57123140A (en) 1981-01-23 1982-07-31 Sankyo Co Ltd Ml-236b carboxylic acid amine salt and remedy for hyperlipemia containing said salt as active component
JPS57185275A (en) 1981-05-07 1982-11-15 Sankyo Co Ltd Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
US4997848A (en) * 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
US5223415A (en) 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5763653A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Key intermediates in the manufacture of simvastatin
US5763646A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina

Also Published As

Publication number Publication date
HUP0103007A3 (en) 2003-10-28
NZ509583A (en) 2003-10-31
US6838566B2 (en) 2005-01-04
CN1228304C (zh) 2005-11-23
EP1114021A1 (en) 2001-07-11
JP2002526467A (ja) 2002-08-20
IL142055A0 (en) 2002-03-10
KR100699368B1 (ko) 2007-03-27
AU765373B2 (en) 2003-09-18
JP3834203B2 (ja) 2006-10-18
AU5528599A (en) 2000-04-10
US20080188552A1 (en) 2008-08-07
HUP0103007A2 (hu) 2002-05-29
EP1114021B1 (en) 2004-07-14
US6583295B1 (en) 2003-06-24
US20050049422A1 (en) 2005-03-03
SI20070A (sl) 2000-04-30
ATE271026T1 (de) 2004-07-15
DE69918697T2 (de) 2005-07-28
CA2343646A1 (en) 2000-03-30
US20030120086A1 (en) 2003-06-26
EP1466886A2 (en) 2004-10-13
WO2000017150A1 (en) 2000-03-30
AU765373C (en) 2005-05-26
KR20010071959A (ko) 2001-07-31
DE69918697D1 (de) 2004-08-19
CN1318046A (zh) 2001-10-17
EP1466886A3 (en) 2009-02-25
IS2113B (is) 2006-06-15
IL142055A (en) 2004-06-20

Similar Documents

Publication Publication Date Title
IS5891A (is) Ný sölt HMG-CoA redúktasatálma
IL187261A0 (en) Crystals of the sodium salt of pravastatin
TR200101235T2 (tr) HMG-CoA Redüktaz inhibitörü içeren durağan farmasötik formül
NO20025784D0 (no) Stabilisert farmasöytisk effektiv sammensetning og farmasöytisk formuleringsom innbefatter samme
YU81800A (sh) POSTUPAK ZA DOBIJANJE INHIBITORA HMG-CoA REDUKTAZE VISOKE ČISTOĆE
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
ATE164886T1 (de) Biochemische reinigung von simvastatin
DK0517413T3 (da) Fermentering af en triol-heptansyre ved mutante stammer af Aspergillus terreus
IE842592L (en) Preparing pyranones
CA2053000A1 (en) Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula
NZ535910A (en) Preparation of amorphous HMG-CoA reductase inhibitors and hydrates thereof by dissolving a heterogeneous mixture of the enzyme in a hydroxylic solvent and freeze drying
ATE418979T2 (de) Stabilisiertes arzneimittel und arzneizubereitung
YU88602A (sh) Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže